5-HT	5-hydroxytryptamine
5-MeO-DMT	5-methoxy-N, N-dimethyltryptamine
AEs	Adverse events
AMPA	α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
APA	American Psychological Association (2019)
AXS-05	Dextromethorphan and bupropion combination
BDNF	Brain-derived neurotrophic factor
CBT	Cognitive behavioral therapy
CGI-I	Clinical Global Impressions Scale
CANMAT	Canadian Network for Mood and Anxiety Treatments
DHA	Docosahexaenoic acid
DALYs	Disability-adjusted life years
DMT	N, N-Dimethyltryptamine
EPA	Eicosapentaenoic acid
ER	Extended release
GABA	Gamma-aminobutyric acid
GAD	Generalized anxiety disorder
HAM-A	Hamilton Anxiety Rating Scale
HAMD-17	Hamilton Depression Rating Scale—17 item
HPA	Hypothalamus-pituitary-adrenal
hs-CRP	High sensitivity C-reactive protein
IDS-C	Inventory of Depressive Symptomatology—Clinician
IL-1β	Interleukin-1β
LSD	Lysergic Acid Diethylamide
MADRS	Montgomery-Asberg Depression Rating Scale
MAOIs	Monoamine oxidase inhibitors
MAPS	Multidisciplinary Association for Psychedelic Studies
MDD	Major depressive disorder
MDE	Major depressive episode
MDMA	Methylenedioxymethamphetamine
NMDAR	N-methyl-D-aspartate receptor
NTRMDD	Non-treatment-resistant major depressive disorder
OR	Odds ratio
PPD	Postpartum depression
PHQ-9	Patient Health Questionnaire-9
PTSD	Post-traumatic stress disorder
rTMS	Repetitive transcranial magnetic stimulation
REMS	Risk Evaluation and Mitigation Strategy
SAT	Standard of care antidepressant therapy
SAMe	S-Adenosyl-L-Methionine
SGAs	Second-generation antidepressants
SHAPS	Snaith–Hamilton Pleasure Scale
SI	Suicidal ideation
SMD	Standardized mean difference
SNRIs	Serotonin–norepinephrine reuptake inhibitors
SSRIs	Selective serotonin reuptake inhibitors
STAR*D	Sequenced Treatment Alternatives to Relieve Depression
TCAs	Tricyclic antidepressants
T3	Triiodothyronine
TRD	Treatment-resistant depression
US FDA	United States Food and Drug Administration
VA/DOD	Veteran Administration/Department of Defense (2022)
YLDs	Years lived with disability